Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-18

Clinical Trial Update: An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma [Phase 3]

View source ↗

Summary

Phase 3 extended-use study of talimogene laherparepvec (T-VEC) in melanoma completed; results assessing safety and efficacy have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Talimogene laherparepvec (talimogene laherparepvec)

Snippet

Sponsor: BioVex Limited | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2015-12-18